Comparison of two novel biomarker panels in ovarian cancer diagnosis for patients with a pelvic mass

R. Macuks, Ieva Baidekalna, Arina Avdejeva, Julia Gritcina, Simona Donina

Research output: Contribution to journalReview articlepeer-review

Abstract

Objective: The study was to measure clinical utility of two biomarker panels for ovarian cancer detection in patients presenting with a pelvic mass- apolipoprotein A1, transferrin, and transthyretin versus Ca125 and HE4. Material And Methods: A case-control study of 93 women was designed-36 patients with ovarian cancer, 30 patients with benign ovarian diseases, and 27 agematched healthy controls. Preoperative serum levels of apolipoprotein A1, transferrin, and transthyretin were measured and linear regression model was built and compared with Risk of Ovarian Malignancy Algorithm (ROMA). Results: When HE4 and Ca125 were incorporated into the ROMA, the mean score for ovarian cancer patients was significantly higher only in the postmenopausal women's group when compared to controls, but not for women in the premenopausal group-84.0±4.3 versus 7.3±0.7 (p<.001) and 46.3±14.0 versus 2.2±0.2 (p=13), respectively. Apolipoprotein A1, transferrin, and transthyretin among postmenopausal women revealed lower coverage of area under the curve (AUC) in comparison to ROMA-.82 versus.98. Sensitivity of combined biomarker model was lower as for ROMA*50.0 versus 96.2% at fixed specificity of 90.0%. Linear regression model derived from three biomarkers among premenopausal women had significantly lower coverage for AUC when compared to ROMA-60 versus.83. Apolipoprotein A1, transferrin, and transthyretin together had higher diagnostic accuracy among early stage epithelial ovarian cancer in comparison to ROMA, but it was conversely for late stage ovarian cancers. Conclusions: Accuracy of ROMA algorithm was more accurate to discriminate patients with late stage ovarian cancers from controls when compared to the diagnostic model calculated from serum levels of apolipoprotein A1, transferrin, and transthyretin and inverse relationship was observed for discrimination of patients with early stage ovarian cancers; however, observation should be confirmed on a larger sample size.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalEuropean journal of Clinical and Medical Oncology
Volume3
Issue number4
Publication statusPublished - 2011

Keywords

  • Apolipoprotein A1
  • Ca125
  • HE4
  • Transferrin
  • Transthyretin

Field of Science

  • 3.2 Clinical medicine

Publication Type

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Comparison of two novel biomarker panels in ovarian cancer diagnosis for patients with a pelvic mass'. Together they form a unique fingerprint.

Cite this